A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098
Sign Up to like & getrecommendations! Published in 2018 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noy078
Abstract: Background GSK2256098 is a novel oral focal adhesion kinase (FAK) inhibitor. Preclinical studies demonstrate growth inhibition in glioblastoma cell lines. However, rodent studies indicate limited blood-brain barrier (BBB) penetration. In this expansion cohort within a… read more here.
Keywords: focal adhesion; adhesion kinase; recurrent glioblastoma; gsk2256098 ... See more keywords